BlossomHill to Present at 44th J.P. Morgan Healthcare Conference
05 Jan 2026 //
GLOBENEWSWIRE
Blossomhill Therapeutics Secures $84M To Advance Cancer Drug
10 Dec 2025 //
GLOBENEWSWIRE
Blossomhill Therapeutics Presents BH-30236, Phase 1 Study Design
03 Nov 2025 //
GLOBENEWSWIRE
Blossomhill Reveals BH-30643 Phase 1/2 SOLARA Trial Results
24 Oct 2025 //
GLOBENEWSWIRE
Blossomhill To Present BH-30643, Phase 1/2 SOLARA Trial Results
14 Oct 2025 //
GLOBENEWSWIRE
BlossomHill`s First Patient Dosed in Phase 1/2 SOLARA Trial
22 Aug 2025 //
GLOBENEWSWIRE
BlossomHill Therapeutics Names Jason Keyes CFO and EVP
09 May 2025 //
GLOBENEWSWIRE
BlossomHill Therapeutics to Present BH-30643 at 2025 AACR Meeting
03 Apr 2025 //
BUSINESSWIRE
BlossomHill Doses 1st Cohort in Ph 1/2 Trial for EGFR-HER2 NSCLC
22 Jan 2025 //
BUSINESSWIRE
BlossomHill Appoints Geoff Oxnard As CMO And EVP
06 Jan 2025 //
BUSINESSWIRE
BlossomHill Therapeutics Closes $100 Million Series B Financing
29 Feb 2024 //
BUSINESSWIRE

Market Place
Sourcing Support